Private investment in biotechnology companies continues to churn out startups and support the next stage of drug development for established early-stage firms, despite the rollercoaster rise and fall of public biotech company valuations, with venture capital firms continuing to raise money for new funds and invest the proceeds in new opportunities.
Frazier Healthcare Partners in Menlo Park, California recently closed Frazier Life Sciences VIII LP with $262m to fund companies that...